ContraFect Corp.
(NASDAQ : CFRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.01%90.691.3%$838.74m
AMGNAmgen Inc.
0.89%188.341.2%$621.82m
GILDGilead Sciences, Inc.
1.84%67.590.9%$512.40m
BIIBBiogen Inc.
2.51%332.871.3%$445.54m
REGNRegeneron Pharmaceuticals, Inc.
2.17%423.972.6%$305.14m
ILMNIllumina, Inc.
2.51%299.823.5%$302.67m
VRTXVertex Pharmaceuticals Incorporated
1.27%188.071.9%$269.75m
ALXNAlexion Pharmaceuticals, Inc.
2.77%129.422.0%$233.68m
LOXOLoxo Oncology Inc
-0.03%234.6612.7%$170.39m
SRPTSarepta Therapeutics, Inc.
2.65%138.4515.4%$148.57m
AAgilent Technologies, Inc.
1.64%78.281.6%$133.87m
INCYIncyte Corporation
0.88%84.152.5%$132.72m
EXASExact Sciences Corporation
0.49%88.5525.3%$128.36m
ARRYArray BioPharma Inc.
4.95%23.138.2%$105.79m
EXELExelixis, Inc.
-0.18%22.266.4%$97.74m

Company Profile

ContraFect Corp. engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.